Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Price:
14.8
USD
2.99%
Market Closed
Market Cap:
$2B
Relative Value
The Relative Value of one
AUPH
stock under the Base Case scenario is
10.25
USD.
Compared to the current market price of 14.8 USD,
Aurinia Pharmaceuticals Inc
is
Overvalued by 31%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
AUPH
Relative Value
Base Case
10.25
USD
Overvaluation 31%
Multiples Across Competitors
AUPH Competitors Multiples
Aurinia Pharmaceuticals Inc Competitors
Aurinia Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
2B USD | 6.8 | 6.7 | 12.6 | 14.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
401.3B USD | 6.6 | 95.9 | 15.7 | 21.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD | 5.5 | 26.2 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.4B USD | 6.3 | 21.7 | 13.5 | 16.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
126.8B USD | 10.6 | 32.1 | 24.3 | 25.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.6B USD | 5.7 | 18.1 | 13.6 | 15.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.6B AUD | 3.2 | 34.8 | 11.5 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39B EUR | 11.1 | 35.7 | 38.8 | 39.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
